These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35839519)

  • 1. The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis.
    Ma Y; Lin C; Cai X; Hu S; Zhu X; Lv F; Yang W; Ji L
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):877-886. PubMed ID: 35839519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
    Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
    Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
    Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors and lower limb complications: an updated meta-analysis.
    Lin C; Zhu X; Cai X; Yang W; Lv F; Nie L; Ji L
    Cardiovasc Diabetol; 2021 Apr; 20(1):91. PubMed ID: 33910574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy.
    Cho EH; Park SJ; Han S; Song JH; Lee K; Chung YR
    J Diabetes Res; 2018; 2018():6807219. PubMed ID: 30622970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study.
    Huang ST; Bair PJ; Chang SS; Kao YN; Chen SN; Wang IK; Chiu CW; Chang CT; Shih YH; Li CY; Yu TM
    Clin Pharmacol Ther; 2024 Jan; 115(1):95-103. PubMed ID: 37804230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):575-581. PubMed ID: 37490120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis.
    Zhu X; Lin C; Li L; Hu S; Cai X; Ji L
    Eur J Pharmacol; 2021 Jul; 903():174145. PubMed ID: 33957085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Li D; Yang JY; Wang T; Shen S; Tang H
    Diabetes Metab; 2018 Nov; 44(5):410-414. PubMed ID: 29506779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
    Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
    Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
    Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
    Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation.
    Hu WS; Lin CL
    Acta Diabetol; 2023 Jul; 60(7):981-987. PubMed ID: 37083962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.